Shareholders Foundation, Inc.

Prosensa Holding NV (NASDAQ:RNA) Investor Alert: Deadline in Lawsuit on September 16, 2014

A Deadline is coming up on September 16, 2014 in the lawsuit for investors in Prosensa Holding NV (NASDAQ:RNA and NASDAQ:RNA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

 

San Diego, CA -- (SBWIRE) -- 08/26/2014 -- A deadline is coming up on September 16, 2014 in the lawsuit filed for certain investors of Prosensa Holding NV (NASDAQ:RNA) over alleged securities laws violations by Prosensa Holding NV.

Investors who purchased a significant amount of shares of Prosensa Holding NV (NASDAQ:RNA) have certain options and there are strict and short deadlines running. Deadline: September 16, 2014. Prosensa Holding NV (NASDAQ:RNA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Prosensa Holding NV (NASDAQ:RNA) pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s initial public offering (“IPO”) on or about June 28, 2013,, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff alleges that the Registration Statement contained materially false and/or misleading statements and/or omitted material information concerning the development status of drisapersen, the drug’s Phase II and Phase III clinical studies, and the prospects for drisapersen’s regulatory approval.

On Sept. 20, 2013, GlaxoSmithKline and Prosensa Holding NV announced that the Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy patients with an amenable mutation, did not meet the primary endpoint of a statistically significant improvement in the 6 Minute Walking Distance test compared to placebo. Shares of Prosensa Holding NV (NASDAQ:RNA) dropped from $24.00 per share on Sept. 19, 2013, to as low as $3.60 per share on November 1, 2013.

Those who purchased shares of Prosensa Holding NV (NASDAQ:RNA) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com